Thomas O Bergmeijer1, Jean-Luc Reny2, Ruth E Pakyz3, Li Gong4, Joshua P Lewis3, Eun-Young Kim5, Daniel Aradi6, Israel Fernandez-Cadenas7, Richard B Horenstein3, Ming Ta Michael Lee8, Ryan M Whaley4, Joan Montaner9, Gian Franco Gensini10, John H Cleator11, Kiyuk Chang12, Lene Holmvang13, Willibald Hochholzer14, Dan M Roden15, Stefan Winter16, Russ B Altman17, Dimitrios Alexopoulos18, Ho-Sook Kim19, Jean-Pierre Déry20, Meinrad Gawaz21, Kevin Bliden22, Marco Valgimigli23, Rossella Marcucci24, Gianluca Campo25, Elke Schaeffeler16, Nadia P Dridi13, Ming-Shien Wen26, Jae Gook Shin19, Tabassome Simon27, Pierre Fontana28, Betti Giusti24, Tobias Geisler21, Michiaki Kubo29, Dietmar Trenk21, Jolanta M Siller-Matula30, Jurriën M Ten Berg1, Paul A Gurbel22, Jean-Sebastien Hulot31, Braxton D Mitchell32, Matthias Schwab33, Marylyn DeRiggi Ritchie34, Teri E Klein35, Alan R Shuldiner36. 1. St Antonius Center for Platelet Function Research, Department of Cardiology, St Antonius Hospital Nieuwegein, the Netherlands. 2. Internal Medicine, Béziers Hospital, France, Geneva Platelet Group, University of Geneva School of Medicine, Department of Internal Medicine, Rehabilitation and Geriatrics, University Hospitals of Geneva, Geneva, Switzerland. 3. Department of Medicine, Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 4. Department of Biomedical Data Science, Stanford University, Stanford, CA, USA. 5. Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, South Korea. 6. Heart Center Balatonfüred and Heart and Vascular Center, Semmelweis University, Budapest, Hungary. 7. Stroke Pharmacogenomics and Genetics, Fundació Docència i Recerca Mútua Terrassa, Neurovascular Research Laboratory, Valle d'Hebron Hebron Institute of Research, Barcelona, Spain. 8. Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA. 9. Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Barcelona, Spain. 10. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 11. Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA. 12. Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 13. Department of Cardiology and Cardiac Catheterization Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 14. University Heart Center Freiburg, Bad Krozingen, Department of Cardiology and Angiology II, Bad Krozingen, Germany. 15. Departments of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, USA. 16. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen, Germany. 17. Department of Biomedical Data Science, Stanford University, Stanford, CA, USA; Departments of Bioengineering and Genetics, Stanford University, Stanford, CA, USA; Department of Medicine, Stanford University, Stanford, CA, USA. 18. Department of Cardiology, Patras University Hospital, Patras, Greece. 19. Department of Pharmacology and Pharmacogenomics Research Center, College of Medicine, Inje University, Busan, South Korea. 20. Quebec Heart and Lung Institute, Québec, Canada. 21. Department of Cardiology and Cardiovascular Medicine, University Hospital Tübingen, Tübingen, Germany. 22. Inova Center for Thrombosis Research and Drug Development. Inova Heart and Vascular Institute, Falls Church, VA, USA. 23. Department of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland. 24. Department of Experimental and Clinical Medicine, University of Florence, Atherothrombotic Diseases Center, Careggi Hospital, Florence, Italy. 25. Cardiology Unit, Azienda Ospedaliera Universitria di Ferrara, Cona (FE) and Maria Cecilia Hospital, GVM Care and Research, Cotignola, (RA), Italy. 26. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and School of Medicine, Chang Gung University, Taoyuan City, Taiwan. 27. APHP, Saint Antoine Hospital, Paris, France. 28. Geneva Platelet Group, University of Geneva School of Medicine, Division of Angiology and Haemostasis, University Hospitals of Geneva, Geneva, Switzerland. 29. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan. 30. Department of Cardiology, Medical University of Vienna, Vienna, Austria. 31. Sorbonne Universités, UPMC Univ Paris 06, Institute of Cardiometabolism and Nutrition (ICAN), Pitié-Salpêtrière Hospital, F-75013 Paris, France. 32. Department of Medicine, University of Maryland, Baltimore, MD, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center, Baltimore, MD. 33. Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tübingen, Germany; Department of Clinical Pharmacology, University Hospital, Tübingen, Germany. 34. Department of Biomedical and Translational Informatics, Geisinger Health System, Danville, PA, USA. 35. Department of Biomedical Data Science, Stanford University, Stanford, CA, USA; Department of Medicine, Stanford University, Stanford, CA, USA. 36. Department of Medicine, Program for Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: ashuldin@som.umaryland.edu.
Abstract
RATIONALE: The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response. STUDY DESIGN: Based on the data published on www.clinicaltrials.gov, clopidogrel intervention studies containing genetic and platelet function data were identified for participation. Lead investigators were invited to share DNA samples, platelet function test results, patient characteristics, and cardiovascular outcomes to perform candidate gene and genome-wide studies. RESULTS: In total, 17 study sites from 13 countries participate in the ICPC, contributing individual patient data from 8,829 patients. Available adenosine diphosphate-stimulated platelet function tests included vasodilator-stimulated phosphoprotein assay, light transmittance aggregometry, and the VerifyNow P2Y12 assay. A proof-of-principle analysis based on genotype data provided by each group showed a strong and consistent association between CYP2C19*2 and platelet reactivity (P value=5.1 × 10-40). CONCLUSION: The ICPC aims to identify new loci influencing clopidogrel efficacy by using state-of-the-art genetic approaches in a large cohort of clopidogrel-treated patients to better understand the genetic basis of on-treatment response variability.
RATIONALE: The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response. STUDY DESIGN: Based on the data published on www.clinicaltrials.gov, clopidogrel intervention studies containing genetic and platelet function data were identified for participation. Lead investigators were invited to share DNA samples, platelet function test results, patient characteristics, and cardiovascular outcomes to perform candidate gene and genome-wide studies. RESULTS: In total, 17 study sites from 13 countries participate in the ICPC, contributing individual patient data from 8,829 patients. Available adenosine diphosphate-stimulated platelet function tests included vasodilator-stimulated phosphoprotein assay, light transmittance aggregometry, and the VerifyNow P2Y12 assay. A proof-of-principle analysis based on genotype data provided by each group showed a strong and consistent association between CYP2C19*2 and platelet reactivity (P value=5.1 × 10-40). CONCLUSION: The ICPC aims to identify new loci influencing clopidogrel efficacy by using state-of-the-art genetic approaches in a large cohort of clopidogrel-treated patients to better understand the genetic basis of on-treatment response variability.
Authors: Glenn N Levine; Eric R Bates; James C Blankenship; Steven R Bailey; John A Bittl; Bojan Cercek; Charles E Chambers; Stephen G Ellis; Robert A Guyton; Steven M Hollenberg; Umesh N Khot; Richard A Lange; Laura Mauri; Roxana Mehran; Issam D Moussa; Debabrata Mukherjee; Brahmajee K Nallamothu; Henry H Ting Journal: Circulation Date: 2011-11-07 Impact factor: 29.690
Authors: Ankie M Harmsze; Jochem W van Werkum; Jurriën M Ten Berg; Bastiaan Zwart; Heleen J Bouman; Nicoline J Breet; Arnoud W J van 't Hof; Hendrik J T Ruven; Christian M Hackeng; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer Journal: Eur Heart J Date: 2010-09-10 Impact factor: 29.983
Authors: Heleen J Bouman; Ankie M Harmsze; Jochem W van Werkum; Nicoline J Breet; Th O Bergmeijer; Hugo Ten Cate; Christian M Hackeng; Vera H M Deneer; Jurriën M Ten Berg Journal: Heart Date: 2011-05-31 Impact factor: 5.994
Authors: Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski Journal: EuroIntervention Date: 2015-01 Impact factor: 6.534
Authors: S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner Journal: Clin Pharmacol Ther Date: 2011-06-29 Impact factor: 6.875
Authors: Ankie M Harmsze; Jochem W van Werkum; Christian M Hackeng; Hendrik J T Ruven; Johannes C Kelder; Heleen J Bouman; Nicoline J Breet; Jurriën M Ten Berg; Olaf H Klungel; Anthonius de Boer; Vera H M Deneer Journal: Pharmacogenet Genomics Date: 2012-03 Impact factor: 2.089
Authors: S A Scott; J-P Collet; U Baber; Y Yang; I Peter; M Linderman; J Sload; W Qiao; A S Kini; S K Sharma; R J Desnick; V Fuster; R J Hajjar; G Montalescot; J-S Hulot Journal: Clin Pharmacol Ther Date: 2016-06-20 Impact factor: 6.875
Authors: Caroline F Thorn; Michelle Whirl-Carrillo; Houda Hachad; Julie A Johnson; Ellen M McDonagh; Mark J Ratain; Mary V Relling; Stuart A Scott; Russ B Altman; Teri E Klein Journal: Clin Pharmacol Ther Date: 2019-01 Impact factor: 6.875
Authors: Meghan J Chenoweth; Kathleen M Giacomini; Munir Pirmohamed; Susan L Hill; Ron H N van Schaik; Matthias Schwab; Alan R Shuldiner; Mary V Relling; Rachel F Tyndale Journal: Clin Pharmacol Ther Date: 2019-11-06 Impact factor: 6.875
Authors: Joshua P Lewis; Joshua D Backman; Jean-Luc Reny; Thomas O Bergmeijer; Braxton D Mitchell; Marylyn D Ritchie; Jean-Pierre Déry; Ruth E Pakyz; Li Gong; Kathleen Ryan; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Meinrad Gawaz; Kevin P Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Matthias Schwab; Teri E Klein; Alan R Shuldiner Journal: Eur Heart J Cardiovasc Pharmacother Date: 2020-07-01
Authors: Mariana R Botton; Michelle Whirl-Carrillo; Andria L Del Tredici; Katrin Sangkuhl; Larisa H Cavallari; José A G Agúndez; Jorge Duconge; Ming Ta Michael Lee; Erica L Woodahl; Karla Claudio-Campos; Ann K Daly; Teri E Klein; Victoria M Pratt; Stuart A Scott; Andrea Gaedigk Journal: Clin Pharmacol Ther Date: 2020-07-22 Impact factor: 6.875
Authors: Ayesha Muhammad; Ida T Aka; Kelly A Birdwell; Adam S Gordon; Dan M Roden; Wei-Qi Wei; Jonathan D Mosley; Sara L Van Driest Journal: Clin Pharmacol Ther Date: 2021-07-12 Impact factor: 6.903
Authors: Nasir Ali Afsar; Henrike Bruckmueller; Anneke Nina Werk; Muhammad Kashif Nisar; H R Ahmad; Ingolf Cascorbi Journal: Sci Rep Date: 2019-05-13 Impact factor: 4.379
Authors: Małgorzata Ostrowska; Jacek Kubica; Piotr Adamski; Aldona Kubica; Ceren Eyileten; Marek Postula; Aurel Toma; Christian Hengstenberg; Jolanta M Siller-Matula Journal: Front Cardiovasc Med Date: 2019-12-03